FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Volume 348:879-880 March 6, 2003 Number 10 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear Related Article by Sandler, R. S. Related Article by Baron, J. A. PubMed Citation

Awareness of the substantial morbidity and mortality attributable to colorectal cancer has focused attention on early detection and prevention through screening and on other strategies such as chemoprevention. Among several agents under evaluation, aspirin appears to have the inside track. Could aspirin reduce the burden of disease associated with the second-leading cause of cancer-related death in the United States?

A protective effect of aspirin is biologically plausible. Aspirin works in part through the inhibition of cyclooxygenase-2, an enzyme that is found in colorectal cancer tissue. Epidemiologic studies have shown a consistent 40 to 50 percent reduction in the risk of . . . [Full Text of this Article]

Source Information

From the Indiana University School of Medicine, the Roudebush Veterans Affairs Medical Center, and the Regenstrief Institute — all in Indianapolis.

This article has been cited by other articles:

• Hubner, R. A., Muir, K. R., Liu, J.-F., Logan, R. F.A., Grainge, M. J., Houlston, R. S., Members of the UKCAP Consortium, (2008). Ornithine Decarboxylase G316A Genotype Is Prognostic for Colorectal Adenoma Recurrence and Predicts Efficacy of Aspirin Chemoprevention. Clin. Cancer Res. 14: 2303-2309 [Abstract] [Full Text]  
• Sangha, S, Yao, M, Wolfe, M M (2005). Non-steroidal anti-inflammatory drugs and colorectal cancer prevention. Postgrad. Med. J. 81: 223-227 [Abstract] [Full Text]  
• Chan, A. T., Tranah, G. J., Giovannucci, E. L., Hunter, D. J., Fuchs, C. S. (2005). Genetic Variants in the UGT1A6 Enzyme, Aspirin Use, and the Risk of Colorectal Adenoma. JNCI J Natl Cancer Inst 97: 457-460 [Abstract] [Full Text]  
• Hur, C., Simon, L. S, Gazelle, G S. (2005). Analysis of Aspirin-Associated Risks in Healthy Individuals. The Annals of Pharmacotherapy 39: 51-57 [Abstract] [Full Text]  
• Chiang, N., Bermudez, E. A., Ridker, P. M., Hurwitz, S., Serhan, C. N. (2004). Aspirin triggers antiinflammatory 15-epi-lipoxin A4 and inhibits thromboxane in a randomized human trial. Proc. Natl. Acad. Sci. USA 101: 15178-15183 [Abstract] [Full Text]  
• Greenberger, N. J., Sharma, P. (2004). Update in Gastroenterology and Hepatology. ANN INTERN MED 141: 374-380 [Full Text]  
• Levin, R. I. (2004). Theriac found? Nitric oxide-aspirin and the search for the universal cure. J Am Coll Cardiol 44: 642-643 [Full Text]  
• Hur, C., Nishioka, N. S., Gazelle, G. S. (2004). Cost-Effectiveness of Aspirin Chemoprevention for Barrett's Esophagus. JNCI J Natl Cancer Inst 96: 316-325 [Abstract] [Full Text]  
• Chan, A. T., Giovannucci, E. L., Schernhammer, E. S., Colditz, G. A., Hunter, D. J., Willett, W. C., Fuchs, C. S. (2004). A Prospective Study of Aspirin Use and the Risk for Colorectal Adenoma. ANN INTERN MED 140: 157-166 [Abstract] [Full Text]  
• (2003). Aspirin and Recurrent Colorectal Adenomas. JWatch Gastroenterology 2003: 2-2 [Full Text]  
• (2003). Does Aspirin Prevent Development of Colorectal Polyps?. JWatch General 2003: 1-1 [Full Text]  
• Vainio, H. (2002). The need for preventive drugs and vaccines in global cancer control: a challenge for public health and for industry. Toxicol Ind Health 18: 84-90 [Abstract]